Truist analyst Jailendra Singh raised the firm’s price target on Medline (MDLN) to $56 from $52 and keeps a Buy rating on the shares. The firm updated its 2026/2027 revenue and adjusted EBITDA estimates following the company’s Q4 report, noting that it’s higher price target multiple reflects the view that there is meaningful upside embedded within the company’s 2026 guidance. There is also meaningful upside in the firm’s estimates for 2026 and 2027, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Conservative 2026 Guidance and Strong Segment Fundamentals Underpin Buy Rating and $53 Target for Medline
- Medline price target raised to $54 from $49 at Goldman Sachs
- Medline price target raised to $47 from $42 at Wells Fargo
- Medline price target raised to $56 from $48 at Baird
- Medline price target raised to $54 from $45 at BMO Capital